BOULDER, Colo. (Nov. 30, 1999) Array BioPharma, Inc. today announced the appointment of Robert E. Conway, 45, as chief executive officer effective Nov. 15, 1999. Conway has also been elected to the Array BioPharma board of directors.
Conway joins Array after three years at Hill Top Research, Ltd. as executive vice president and chief operating officer, where he managed 22 company-owned research centers conducting clinical trials for pharmaceutical and biotech companies. Prior to joining Hill Top, Conway was the corporate vice president and general manager of Corning Hazleton, Inc., the world’s largest preclinical contract research organization. There, he led North American operations consisting of two state-of-the art laboratories, three worldwide sales offices and 1,025 employees.
“The addition of Bob Conway as CEO at Array BioPharma is a significant enhancement to Array’s management team,” said Kyle Lefkoff, chairman of Array’s board of directors and its lead venture capital investor through Boulder Ventures, Inc. “The success and growth of Array over the last year reflects the outstanding efforts of its current management and employees. Bob’s experience and skills will help drive Array in its mission to become a key partner with the pharmaceutical industry as it looks to outsource medicinal chemistry in the new millennium.”
“We are delighted to have Bob on board at Array,” said David Snitman, chief operating officer and vice president of business development. “Bob Conway brings the experience we need to help manage our rapid growth.”
“Having Bob Conway on our management team will allow us all to focus effectively on growing the company,” said Kevin Koch, president and chief scientific officer. “With this talented team in place, we are truly positioned to be a powerful force in enhancing our customer’s drug discovery process.”
Array is a privately held discovery research organization (DRO™) providing research services in all aspects of chemistry, high-throughput screening, structural biology and information management. Array complements the experience of its researchers with proprietary drug discovery tools, including unique sets of building blocks called monomer arrays for automated lead explosion, pharmacophore-biased small molecule libraries, high-speed synthesis automation, X-ray crystallography and qualifying human drug metabolism assays. For additional information, visit the company’s web site at www.arraybiopharma.com.